SciELO - Scientific Electronic Library Online

 
vol.130 número6Enfermedad hepática alcohólica: desde el daño molecular a su tratamientoAvances tecnológicos: La radiología que viene índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

PONIACHIK T, Jaime; QUERA P, Rodrigo  y  LUI G, Andrea. Fulminant hepatic failure. Rev. méd. Chile [online]. 2002, vol.130, n.6, pp.191-198. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872002000600014.

Fulminant hepatic failure (FHF) is an acute and eventually fatal illness, caused by a severe hepatocyte damage with massive necrosis. Its hallmarks are hepatic encephalopathy and a prolonged prothrombin time (<40%). FHF is currently defined as hyperacute (encephalopathy appearing within 7 days of the onset of jaundice), acute (encephalopathy appearing between 8 and 28 days) or subacute (encephalopathy appearing between 5 and 12 weeks). FHF can be caused by viruses, drugs, toxins, and miscellaneous conditions such as Wilson’s disease, Budd-Chiari syndrome, ischemia and others. However, a single most common etiology is still not defined. Factors that are valuable in assessing the likelihood of spontaneous recovery are age, etiology, degree of encephalopathy, prothrombin time and serum bilirubin. The management is based in the early treatment of infections, hemodynamic abnormalities, cerebral edema, and other associated conditions. Liver transplant has emerged as the most important advance in the therapy of FHF, with a survival rate that ranges between 60 and 80%. The use of hepatic support systems, extracorporeal liver support and auxiliary liver transplantation are innovative therapies (Rev Méd Chile 2002; 130: 691-698).

Palabras clave : Hepatic encephalopathy; Hepatic failure, fulminant; Hypoprothrombinemia; Liver transplantation; Prothrombin.

        · texto en Español

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons